Arca
Skip to content

Acute myeloid leukemia

Drug research and approvals for acute myeloid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 607 studies of acute myeloid leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 88 drug trials for it since 2013, and FDA has 22 approved and 156 open orphan designations naming it.

  • Recruiting worldwide: 607
  • Trials authorized in Canada: 88
  • FDA orphan approvals: 22
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 607 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 88; search them all in Canada trials
Oct 14, 2026A phase I/ib, multi-center, open-label, dose escalation and dose expansion study of fvy281 as monotherapy in adult participants with relapsed/refractory acute…FVY281 / AZACITIDINENovartis Pharmaceuticals CorporationPending
Sep 29, 2026A two-part, phase 2b/phase 3 double-blinded, randomized study of ipn60340 in combination with azacitidine and venetoclax versus placebo in combination with…IPN60340IpsenPending
Sep 25, 2026A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…VICRIMENIB (S243249, BN104)ServierPending
May 27, 2026A phase 1b study of the safety and pharmacokinetics of pivekimab sunirine in pediatric subjects with relapsed or refractory acute myeloid leukemia (aml)PIVEKIMAB SUNIRINE (IMGN-632)AbbViePending
May 26, 2026A phase 2 trial of gilteritinib in combination with azacitidine and venetoclax to overcome venetoclax resistance in patients with relapsed/refractory flt3-wild…GILTERITINIBBC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITYPending
Mar 26, 2026A randomized phase II study of venetoclax and hma-based therapies for the treatment of older and unfit adults with newly diagnosed flt3-mutated acute myeloid…VENETOCLAX (ABT-199) / GILTERITINIB (ASP2215)CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Dec 15, 2025A phase 3, randomized, double-blind, placebo-controlled study of revumenib in combination with intensive chemotherapy in participants with newly diagnosed aml…REVUMENIB (SNDX-5613) / CYTARABINE / DAUNORUBICIN / IDARUBICINSyndax PharmaceuticalsPending
Aug 28, 2025Phase 3 randomized, double-blind, placebo-controlled studies assessing ziftomenib in combination with either standard of care nonintensive…ZIFTOMENIB / VENETOCLAX / AZACITIDINE / DAUNORUBICIN / CYTARABINEKura OncologyOngoing
May 23, 2025A phase 1 study of tak-243 for relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes with increased blastsTAK-243UNIVERSITY HEALTH NETWORKOngoing
Feb 25, 2025A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed…BLEXIMENIB (JNJ-75276617)Johnson & JohnsonOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 178
May 13, 2026Inqoviin combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have…Taiho Oncology Inc.Approved
Nov 13, 2025Komziftitreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who…Kura Oncology, Inc.Approved
Oct 24, 2025Revuforjtreatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric…Syndax Pharmaceuticals, Inc.Approved
Jan 21, 2025Grafapexin combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric…Medac GmbHApproved
Nov 15, 2024Revuforjtreatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric…Syndax Pharmaceuticals, Inc.Approved
Jul 20, 2023Vanflytain combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following…Daiichi Sankyo, Inc.Approved
Dec 1, 2022Rezlidhiatreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)…Rigel Pharmaceuticals, Inc.Approved
May 25, 2022TibsovoIn combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible…Servier Pharmaceuticals LLCApproved
Mar 30, 2021VYXEOS ; Vyxeos ; Vyxeostreatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults…Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)Approved
Sep 1, 2020ONUREGONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or…Bristol-Myers SquibbApproved
Jun 16, 2020MylotargMylotarg¿ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month…Wyeth Pharmaceuticals, Inc., a Pfizer CompanyApproved
May 2, 2019TIBSOVOTIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)…Servier Pharmaceuticals LLCApproved
Nov 28, 2018XOSPATAXOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like…Astellas Pharma US, Inc.Approved
Nov 21, 2018DAURISMODAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult…Pfizer, Inc.Approved
Nov 21, 2018VENCLEXTAVENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute…AbbVie Inc.Approved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.